Health Technology · Supplementary · from Health Technology

Case 3: Wearable Device Detection of Atrial Fibrillation

Patient Presentation

Demographics: 47-year-old male software engineer

Chief Complaint: "My smartwatch keeps telling me I have an irregular heartbeat."

History of Present Illness: A 47-year-old male presents to his primary care physician after his consumer smartwatch (photoplethysmography-based heart rhythm monitoring feature) generated three "irregular rhythm" notifications over the past week. The notifications occurred during periods of rest -- twice while sitting at his desk and once while watching television in the evening. He denies palpitations, chest pain, dyspnea, lightheadedness, or syncope during these episodes.

He purchased the smartwatch 2 months ago primarily for fitness tracking. The device's irregular rhythm notification feature uses a photoplethysmography (PPG) sensor to detect pulse irregularity and, when triggered, prompts the user to record a single-lead electrocardiogram (ECG) via the watch. The patient recorded ECGs during two of the three notifications. Both recordings, which he shows on his smartphone app, demonstrate an irregularly irregular rhythm with absent P waves consistent with atrial fibrillation, with ventricular rates of 92 and 108 bpm and recording durations of 30 seconds each.

The patient has no prior history of atrial fibrillation or cardiac disease. He does report a 3-year history of untreated obstructive sleep apnea (diagnosed by home sleep study but declined CPAP) and drinks 3-4 craft beers on weekend evenings.

Past Medical History:

• Obstructive sleep apnea (moderate, AHI 22; untreated)
• Obesity (BMI 31.4)
• Pre-hypertension

Medications:

• None

Social History:

• Software engineer, sedentary work
• Alcohol: 3-4 beers on Friday and Saturday evenings
• No tobacco or illicit drug use
• Married, two children
• Exercises sporadically (walks 2-3 times per week)

Family History:

• Father: atrial fibrillation diagnosed at age 62, on anticoagulation
• Mother: hypothyroidism

Physical Examination

• Vital Signs: BP 134/82 mmHg, HR 78 bpm (regular at time of visit), RR 14/min, Temp 36.9°C, SpO2 97% on room air, BMI 31.4
• General: Well-appearing, obese male in no acute distress
• HEENT: Mallampati class III, large neck circumference (43 cm)
• Cardiovascular: Regular rate and rhythm at time of exam, no murmurs, rubs, or gallops; no JVD
• Lungs: Clear to auscultation bilaterally
• Extremities: No peripheral edema, pulses 2+ throughout

Workup and Results

Laboratory Studies:

Imaging/Additional Studies:

• Smartwatch ECG recordings (x2): Irregularly irregular rhythm, absent P waves, ventricular rates 92 and 108 bpm, consistent with atrial fibrillation
• In-office 12-lead ECG: Normal sinus rhythm at 78 bpm, no ST changes, normal intervals
• Echocardiogram: Normal LV size and function (EF 60%), left atrial volume index 32 mL/m² (mildly enlarged), no valvular abnormalities
• 14-day continuous ambulatory ECG patch: Three episodes of atrial fibrillation captured (durations 22 minutes, 3.8 hours, and 45 minutes), all asymptomatic; maximum ventricular rate 124 bpm; total AF burden 2.1%
• CHA₂DS₂-VASc Score: 0 (age <65, no HTN, DM, stroke, vascular disease, or female sex)

Clinical Image

Diagram showing the clinical pathway from consumer wearable device irregular rhythm detection through confirmatory medical-grade monitoring and treatment decision-making. Source: Educational illustration.

Diagnosis

Paroxysmal Atrial Fibrillation Detected by Consumer Wearable Device, with Contributing Obstructive Sleep Apnea

Key Diagnostic Criteria:

• Consumer smartwatch PPG sensor detected irregular rhythm on three occasions
• Smartwatch single-lead ECG recordings showed irregularly irregular rhythm without P waves
• Confirmed by 14-day ambulatory ECG monitor: three AF episodes (longest 3.8 hours)
• All episodes asymptomatic
• Left atrial volume mildly enlarged on echocardiogram
• Untreated moderate obstructive sleep apnea as contributing factor

Treatment Plan

1. Anticoagulation decision: CHA₂DS₂-VASc score 0; anticoagulation not currently indicated per guidelines; reassess annually or with development of new risk factors
2. Rate vs. rhythm control: Given low AF burden (2.1%) and asymptomatic episodes, adopt watchful waiting with rate control strategy; no antiarrhythmic drugs at this time
3. Address modifiable risk factors:

• Initiate CPAP therapy for obstructive sleep apnea (treatment of OSA reduces AF recurrence by 40-50%)
• Weight loss counseling (target BMI <30)
• Alcohol moderation (reduce to ≤2 standard drinks/occasion; consider elimination trial)
• Structured exercise program

1. Monitoring: Continue smartwatch monitoring as adjunct; repeat 14-day monitor in 6 months to reassess AF burden
2. Follow-up: Cardiology follow-up in 3 months; reassess symptoms and AF burden; echocardiogram annually to monitor left atrial size

Key Learning Points

• Consumer wearable devices with PPG-based irregular rhythm detection have demonstrated positive predictive values of 71-84% for atrial fibrillation in validation studies
• Wearable-detected arrhythmias require confirmation with medical-grade monitoring (ambulatory ECG patch or Holter) before treatment decisions
• Obstructive sleep apnea is an independent risk factor for atrial fibrillation, and its treatment significantly reduces AF recurrence
• CHA₂DS₂-VASc scoring guides anticoagulation decisions; a score of 0 in males generally does not warrant anticoagulation despite confirmed AF
• The detection of asymptomatic AF by consumer devices raises important clinical questions about screening, overdiagnosis, and the threshold for intervention

All cases for this lecture as Markdown